Clinical trials: Mild Cognitive Impairment Due to Alzheimer's Disease
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Early Alzheimers Disease, Mild Cognitive Impairment Due to AD
A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
This is a phase 2B multicenter, randomized, double-blind, placebo-controlled, parallel group dose finding study to evaluate the safety, tolerability and efficacy of PQ912, an inhibitor of the glutaminyl cyclase enzyme, in 250…
- Trial name
- VIVIAD (NCT04498650)
- Testing
- PQ912
- Where
- 21 sites in Denmark, Germany and 3 more
- Volunteers
- 259 people
- Sponsor
- Vivoryon Therapeutics N.V.
Mild Cognitive Impairment (MCI)
To Evaluate the Safety and Efficacy of RP902 Tablets
The purpose of the study is to evaluate the preliminary efficacy of RP902 Tablets in participants with Alzheimer's disease (AD)-derived mild cognitive impairment (MCI) and provide a design basis for the Phase III study.
- Trial name
- NCT07579884
- Testing
- RP902
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
Alzheimer Disease
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
- Trial name
- NCT06761066
- Testing
- NVP-NK4146
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- NVP Healthcare
Alzheimer Disease
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI…
- Trial name
- NCT06247345
- Testing
- ADEL-Y01 - healty participants, ADEL-Y01 - MCI/AD
- Where
- 6 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
Alzheimer Disease
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
The purpose of this study is to study the effect of monthly dosing with a single dose of Lu AF20513, with and without booster vaccine, on antibody response.
- Trial name
- NCT03819699
- Testing
- Lu AF20513, booster vaccine
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or…
- Trial name
- NCT03019536
- Testing
- LY3303560 - IV, Florbetapir F 18, Flortaucipir F18
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimers Disease
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen.
- Conditions
- Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
- Trial name
- NCT06489548
- Testing
- Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mild Cognitive Impairment
Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions.
- Trial name
- NCT03319810
- Testing
- Octagam 10%
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sutter Health
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour.
- Trial name
- PRImus-AD (NCT06182085)
- Testing
- PRI-002
- Where
- 38 sites in Czechia, Germany and 4 more
- Volunteers
- 304 people
- Sponsor
- PRInnovation GmbH
Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance…
- Trial name
- NCT06058234
- Testing
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
- Where
- United States
- Volunteers
- 8,680 people
- Sponsor
- Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Alzheimer's Disease (AD)
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
- Trial name
- NCT06114745
- Testing
- SHR-1707 injection
- Where
- 3 sites in Australia
- Volunteers
- 2 people
- Sponsor
- Atridia Pty Ltd.
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Mild Cognitive Impairment, Mild Cognitive Impairment Due to Alzheimer's Disease
UK Based Remote Brain Health Clinic (BHC) for Patients With Mild Cognitive Impairment (MCI)
This project aims to understand the feasibility, acceptability and real-world evidence of a novel UK-based remote brain health clinic for patients with mild cognitive impairment (MCI).
- Trial name
- BHC (NCT06379594)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- South London and Maudsley NHS Foundation Trust
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment Due to Alzheimer's Disease, Dementia Due to Alzheimer's Disease (Disorder)
Biomarkers of Cognitive Impairment in Blood Cells
The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease.
- Trial name
- COGNIMARK (NCT05582941)
- Testing
- No intervention will be performed.
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of the Balearic Islands
Alzheimer Disease, Anxiety
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild…
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Trial name
- CBD (NCT04075435)
- Testing
- high CBD/low THC sublingual solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Cognitive Impairment, Mild, Cognitive Dysfunction
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients.
- Conditions
- Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration
- Trial name
- MCLENA-1 (NCT04032626)
- Testing
- Lenalidomide 10 mg
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Mild Cognitive Impairment, Dementia
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.
- Trial name
- NCT05104463
- Where
- 15 sites in United States, New Zealand
- Volunteers
- 64 people
- Sponsor
- CuraSen Therapeutics, Inc.